tiprankstipranks
Kilitch Drugs (India) Limited (IN:KILITCH)
:KILITCH
India Market
Want to see IN:KILITCH full AI Analyst Report?

Kilitch Drugs (India) Limited (KILITCH) Price & Analysis

0 Followers

KILITCH Stock Chart & Stats

₹355.60
₹0.95(0.27%)
At close: 4:00 PM EST
₹355.60
₹0.95(0.27%)

Bulls Say, Bears Say

Bulls Say
Revenue GrowthSustained multi-year revenue scaling indicates expanding commercial footprint and broader product adoption across markets. This durable top-line expansion supports economies of scale, strengthens bargaining power with suppliers, and funds capacity, R&D or geographic expansion over the medium term.
Improved ProfitabilityProfitability improvement to mid-teens operating and net margins signals better cost control or favorable product mix versus earlier years. Higher sustained margins improve earnings quality, increase internal funding capacity for strategic investment, and bolster resilience to industry cycles.
Moderate Leverage & Equity GrowthLeverage remains moderate despite rising debt, while equity expansion and asset growth strengthen balance-sheet capacity. This combination provides room to finance growth or exports and retains borrowing headroom, supporting strategic initiatives if cash-generation trends stabilize.
Bears Say
Negative Free Cash FlowPersistent and worsening negative free cash flow, especially the sharp ~-806M in 2026, indicates weak cash conversion from operations or heavy capex/working-capital deployment. This creates structural funding risk, likely requiring continued external financing and raising long-term cost of capital.
Rising DebtThe steady increase in leverage over recent years reduces financial flexibility. With fragile free-cash conversion, higher debt elevates refinancing and interest-rate exposure, potentially pressuring margins and limiting ability to invest unless operating cash generation improves materially.
Margin CompressionDeclining gross and operating margins in 2026 suggest rising input costs or pricing pressure despite revenue growth. If sustained, margin erosion will weaken profitability and cash generation, making it harder to deleverage, fund capex, or sustain returns to stakeholders over the medium term.

Kilitch Drugs (India) Limited News

KILITCH FAQ

What was Kilitch Drugs (India) Limited’s price range in the past 12 months?
Kilitch Drugs (India) Limited lowest stock price was ₹121.10 and its highest was ₹245.00 in the past 12 months.
    What is Kilitch Drugs (India) Limited’s market cap?
    Kilitch Drugs (India) Limited’s market cap is ₹6.39B.
      When is Kilitch Drugs (India) Limited’s upcoming earnings report date?
      Kilitch Drugs (India) Limited’s upcoming earnings report date is Aug 07, 2026 which is in 72 days.
        How were Kilitch Drugs (India) Limited’s earnings last quarter?
        Kilitch Drugs (India) Limited released its earnings results on May 15, 2026. The company reported ₹4.24 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.24.
          Is Kilitch Drugs (India) Limited overvalued?
          According to Wall Street analysts Kilitch Drugs (India) Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Kilitch Drugs (India) Limited pay dividends?
            Kilitch Drugs (India) Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Kilitch Drugs (India) Limited dividends here
              What is Kilitch Drugs (India) Limited’s EPS estimate?
              Kilitch Drugs (India) Limited’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Kilitch Drugs (India) Limited have?
              Kilitch Drugs (India) Limited has 34,961,563 shares outstanding.
                What happened to Kilitch Drugs (India) Limited’s price movement after its last earnings report?
                Kilitch Drugs (India) Limited reported an EPS of ₹4.24 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.608%.
                  Which hedge fund is a major shareholder of Kilitch Drugs (India) Limited?
                  Currently, no hedge funds are holding shares in IN:KILITCH
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Kilitch Drugs (India) Limited

                    Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.

                    Kilitch Drugs (India) Limited (KILITCH) Earnings & Revenues

                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Albert David Ltd
                    Medicamen Biotech Limited
                    Nectar Lifesciences Ltd.
                    Valiant Laboratories Ltd.
                    Zim Laboratories Ltd.
                    Popular Stocks